Support program for breast cancer pill treatment
Part of Cancer clinical trials.
This study looks at whether supporting patients helps them stick to their prescribed oral breast cancer treatment (abemaciclib and hormone therapy). If you're already taking this combination for early-stage breast cancer, the study team may provide extra guidance to help you stay on track.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have early breast cancer that is hormone-receptor positive (HR+) and HER2 negative (HER2-).
- You are being treated with abemaciclib (a pill) and hormone therapy, having started within the last 28 days or about to start.
- You are not pregnant or breastfeeding.
- Your doctor confirms you have no medical reasons that would make this study unsafe for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows women taking abemaciclib (a targeted cancer drug) for early-stage hormone-receptor-positive breast cancer to understand how the treatment affects their quality of life and health outcomes. The goal is to improve care for people in this situation.
This study tests whether a coaching program based on personality types helps women with early-stage hormone receptor-positive, HER2-negative breast cancer stick to their treatment plan. Participants must be taking ribociclib (Kisqali) and an aromatase inhibitor, and their cancer must not have spread to other organs.
This trial tests whether adding abemaciclib to standard hormone (endocrine) therapy can improve outcomes for certain types of advanced breast cancer. It also uses a phone app to help you and the team track side effects so problems can be caught early.
This study looks at how well a combination of two medicines (a CDK4/6 inhibitor and an aromatase inhibitor) works for people with a certain type of advanced breast cancer. It aims to gather real-world information to better understand treatment patterns and outcomes.
This study uses real-world health records to learn about outcomes in people with hormone-receptor positive, HER2-negative breast cancer who were treated with abemaciclib along with hormone (endocrine) therapy. It may help doctors better understand how well this treatment works outside of clinical trials.
This trial tests whether a higher dose of abemaciclib (a pill that helps stop cancer cells from growing) is safe and effective when used after surgery for early high-risk breast cancer. It is for people whose cancer is hormone receptor positive and HER2 negative, and who will take it along with endocrine therapy (hormone-blocking treatment).
Hear when a new HR+/HER2- Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.